Notably, autologous CAR-T cells have demonstrated exceptional efficacy in hematological malignancies, resulting in multiple FDA approvals for products targeting CD19 and B-cell maturation antigen (BCMA) (4, 5). The gene discussed is CD19; the disease is hematologic disorder.